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The ipratropium solution used in this trial was supplied 




Aim: To detennine whether the addition of nebulised ipratropium to the therapy of acute 
as~hma leads to a cost-effective reduction in the mean duration of admission and time to 
marimum peak expiratory flow rate {PEFR). 
Method: Patients with an admission diagnosis of acute asthma were studied in a double-
blind, placebo-controlled trial in which they received a standard therapeutic regimen of 
continuous intravenous aminophylline, 4-hourly fenoterol nebulisation, intravenous 
methylprednisolone 125mg 12-hourly, and, every four hours, either nebulised saline 
placebo or ipratropium bromide 500mcg in 3ml saline. Data on age, gender, initial and 
maximum PEFR, time to marimum PEFR, and duration of hospital stay was collected 
from the hospital record after discharge. 
Statistical techniques: 2-way contingency tables for categorical variables, 1-way 
ANOVAfor treatment effects, and life-table analysis of the time till discharge. 
Results: Records of 279 of the 400 patients entered in the study were suitable for 
analysis after excluding re-admissions, non-asthmatics and incomplete records. Baseline 
comparisons of age and severity on presentation showed no significant differences. The 
trial group did not differ significantly from the control group with respect to either time 
toPEFR {respectively 21.11 hours (SD 14.3) versus 22.89 (SD 15.82)) or duration of 
admission (5.02 (SD 3.65) versus 5.38 (SD 3.13) 6-hour units). In a sub-group of patients 
(n=155) demonstrating more than 100% improvement in PEFR. the time to nun.imum 
PEFR was significantly shorter in the ipratropium group (20.35 hours SD 12.4) versus 
25.20 hours (SD 17.0); p= 0.045). 
Conclusion: The addition of ipratropium bromide to a standard treatment regimen for 
acute asthma reduced the time to achieve maximum PEFR in a sub-group of patients with 
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Ipratropium has been shown to be effective in acute asthma1.2, and more recently it was 
demonstrated that this effect was additive to that of standard67 asthma regimes6,18.3Ut. 
However, a statistically significant cliffurence in recovery rate is not necessarily clinically 
useful and it would thus seem appropriate to look at the cost-effectiveness of additive 





All decisions in medicine are ultimately related to evaluating the benefits and risks of a 
therapeutic intervention ( or non-intervention) in relation to the expected outcome. Attempts 
to fonnalise this decision process are fraught with di.fficulty1l,3& but several concepts have 
been defined. 
"Cost-effectiveness" compares the cost in financial terms of using a specific intervention 
with outcome measures which are translated into monetary values. An example would be 
comparing the cost of renal transplantation with that of long-term dialysis. 
"Cost-benefit" does not translate outcome into financial terms, but rather uses other units 
such as quality adjusted life years (QAL Ys) or other quantifiable measures of benefit. 
While this has the advantages of seeming more easily clinically interpretable it is perhaps 
more open to inter-observer variation at the level of outcome assessment. 
Traditionally, most medical decisions have been limited to assessing benefit to the 
individual patient, according to the Hippocratic principle of benificence. This viewpoint 
was reinforced in the past by the fact that the majority of therapeutic interventions were 
limited by biotechnology and not by cost. In the public health sector this situation is now 
changing58, and if one takes the concept to its logical extreme, then the model of doctor -
single patient is no longer viable in terms of health economics, and should be replaced by 
the tetmd of doctor - community - individual patient - health resources. By prescribing an 
expensive drug in the face of a limited drug budget, one may be "harming" another of one's 




Interactions to consider when assessing the aspect from which to evaluate a cost-
effectiveness intervention. 
At present there still seems to be ambiguity about the responsibility for resource 
allocation48• While health administrators stress global cost saving measures, it is 
important for clinicians to distinguish between strategies leading to suboptimal care and 
those where a less expensive treatment may be equally efficacious. It is in the light of this 
that any data which helps evaluate the cost-effectiveness (or otherwise) of a strategy 
should be regarded as being ofvalue.s,6. However, as has been emphasiz.ed recently27, 
there are potential haz.ards with studies of this type, such as: 
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1. Unstandardized methodology. As this is a relatively new field, some of the 
assumptions made by the investigators may not be clear to readers of the study, eg precise 
data on costing. 
2. Negative results. Becaus~ economic analysis is sometimes regarded more 
as a marketing strategy than a research tool there may be some reluctance to publish 
negative results.27. 
3.Comparative agents. There may sometimes be inherent bias in that the 
agent under investigation may be compared with other agents with known efficacy but 
unfavourable cost profiles. 
4.Frame of reference. As mentioned previously, the beneficiaries of the cost-
effective strategy should be clearly defined, eg, hospital, patient or third party supplier. 
7 
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ii Trial design and 1ype 2 errors 
Many of the studies on the use of ipratropium in asthma are of relatively low power (small 
numbers of patients), as will be shown later. It has been pointed out that these studies are 
open to type 2 errors68, where the finding of a negative result should be interpreted with 
caution ( a clinically significant difference between groups may fail to achieve statistical 
significance if the groups are small). 
Also, highly selected groups of subjects tend to be used in trials designed to assess the 
biological effect of an agent, eg when evaluating a new bronchodilator only young patients 
with previously defined highly reversible asthma might be studied. Strikingly different 
outcomes regarding both efficacy and adverse effects may, however, occur in clinical 
practice, a phenomenon best evaluated by post-marketing surveillance and other 
pbannaco-epidemiological methods. 
For this reason it was decided that in this trial of cost-effectiveness an attempt would be 
made to recruit relatively large numbers of patients, unselected except for the fact that they 
were judged by casualty medical officers to have acute asthma requiring hospital 
admission. 
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iii. Historical backgr01md 
The fact that anticholinergic medication has been used for asthma for many centuries43,61 
is a pointer to its therapeutic efficacy, but may also have something to do with the more 
ready bio-availability of atropine-like alkaloids in plants such as Datum strammonium and 
the lack of other remedies with consistent efficacy. 
Ayurvedic texts discuss dosage!': 
"When the chest, throat and head become light and the cough is reduced, one should 
regard it as the result of proper smoking. When the sound (?wheeze) is not clear, the 
throat is full of cough and the head is moist, one should know that smoking has been 
inadequate." 
and side-effects: 
"If one oversmokes, his palate, head and throat will be dried up and will be hot; he will 
suffer from thirst and be unconscious; there will be excessive flow of blood, his head will 
be dizzy, and he will be stupefied. "19 
Although probably not the earliest user in Britain, a surgeon called William English 
described the effects of Datura smoke in 1811 : 
" ... the irritation and constant cough ceased, and I expectorated from the bronchia pieces 
of clear congealed phlegm, from half an inch to about an inch in length, and the 
thickness of a crow's quill, which enabled me to fill the chest with air''19_ 
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Even as late as 1959, smoke-home anticholinergic therapy was still being advocated by 
Hencheimer26 (" Atropine cigarettes in asthma and emphysema"), and studies from the mid-
seventies demonstrated some benefit from the use of atropine nebulisation. However the 
narrow margin between efficacy and toxicity prevented atropine from finding much favour 
in clinical practice, and it was only with the synthesis of Sch 1000 (ipratropium) that 
anticholinergic therapy in asthma was once again popularised.23.2",43,62,65. 
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iv. Nebuliz;er theozy 
The physics of particle deposition from nebulizer devices involves consideration of features 
such as the volume of solution used, the breathing pattern of the patient, and the type of 
aiJways disease. Particle deposition in a branching tubular system occurs by a combination 
of impaction and sedimentation, with the nett result that there are preferential sites for 
deposition of particles of different sizes. Broadly spMkiog, however, the following features 
are the most important. S.SO. 
1. Volume ofnebnljz;er solution. It appears that minimum volumes of 4-6 ml are required, 
as up to 50% of the solution may remain in the apparatus, even when the reseivoir appears 
to be empty'9• 
2. Flow rate of the driving gas. If jet nebulizers are operated at only 4 //min, the aerosol 
particle sire may lie outside the optimum range, and thus flow rates of 6-8 //min have been 
recommended. The "ideal" particle sire is difficult to determine because of confounding 
variables such as evaporation, hygroscopic growth, aggregai:ion and the normal fairly wide 
range in particle sire from a conventional system. Particles less than 1 um in diameter tend 
to either get exhaled or settle in the alveoli, whilst particles bigger than 8 um are usually 
trapped in the oropharynx. Particles ranging in sire from 1-5 um are likely to reach most 
parts of the lungs and thus a mass mean aerodynamic diameter (MMAD) ofless than 5 
um with a geometric standard deviation of <2 has been recommended8. 
3 .Drug dose, When determining the appropriate dose" it must be borne in mind that only 
about 100/o or less of the dispensed amount will actually reach the lungsS.SO. 
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4.Pattem of jnha]ation. Published investigations on differences in particle deposition 
related to forced inspiration versus tidal breathing, and on the increased sedimentation 
related to inspiratocy pauses mainly apply to metered dose inhalers. For jet nebulimtion 
therapy the avoidance of excessive oropharyngeal deposition due to too rapid inhalation is, 
however, probably advisable. 
5.Aiiways disease, Patchy distribution of particle deposition in airways obstruction has 
been described"9.There also seems to be a more central deposition in these patients when 
compared to subjects without obstructive lung disease. Airways inflammation may 
enhance drug delivery to receptors due to increased vascularity and mucus production. 
v. Airway innervation 
Although more recent reviews1s,3s,,s of the pathogenesis and treatment of asthma lay 
particular emphasis on the inflammatory nattJ.re10.tJ,ts,1o,19,30,31,51 of the disease, the final 
common pathway is still bronchoconstriction, 33,34,56, 72 and treatment directed at acute 
exacerbations must recognise fuis.21,34. Airway tone is thought to be due to at least four 
factors : 
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1. Cholinergic neurones: Excitation of these neurones3 leads to the endplate 
release of acetylcholine, the transmitter which causes the formation of excitatory 
postjunctional potentials leading to increased bronchomotor tone. Repetitive cholinergic 
stimulation may lead to the release of prostanoids and noradrenaline, which inhibit 
acetylcholine release, thus acting as a form of negative feedback. This pathway is central to 
the presumed mechanism of action of ipratropium. 
2. Aclreruqic wecbaoisms: Although there is probably no direct sympathetic 
innervation of the airways in humans, the fact that B-blockers may cause 
bronchoconstriction in asthmatics lends support to the theory that circulating 
catecholamines may inhibit cholinergic transmission either at a pre-junctional level or may 
act directly on B2 receptors on bronchial smooth muscle. 
3.NANC neurones: Non-adrenergic non-cholinergic effects are probably due to 
co-release of neuropeptides and other transmitters from "conventional" fibres, rather than 
there being a separate set of neurones4. Inhibitory non-adrenergic non-cholinergic (i-
NANC)mechanisms lead to bronchodilatation, and although there is still debate about the 
neurotransmitters involved, vaso-activc intestinal peptide (VIP) probably plays a part, as 
may nitric oxide (NO). In asthmatics, tryptase from mast cells may increase the rate of 
breakdown of VIP, and free radical release from other inflammatory cells may lead to the 
more rapid degradation of NO. When C-fibre sensory nerves are stimulated, there may also 
be retrograde release of neuropeptides - eg substance P and neurokinin A - leading to 
bronchoconstriction (the so-called excitatory non-adrenergic non-cholinergic or e-NANC 
effect)'. This increased sensory output is speculated to be more likely in the setting of 
epithelial inflammation 
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4."Mechaoical" tone: this is thought to be due to the local release of endogenous 
prostanoids and possibly other mediators, and through release of calcium from intracellular 
stores leads to the generation of some intrinsic muscle tone that is not due to external 
neuronal input. 
The basic contractile mechanism is fairly well established: neurotransmitter-receptor 
binding leads to the generation of increased myoplasmic calcium concentrations, the 
calcium binds to calmodulin, and this complex activates the enzyme myosin ljgbt cbaio 
kinase., which leads to the phosphorylation of the 20 OOOD myosin subunits, and 
subsequent mechanical activation of the actin-myosin complex with resultant shortening of 
the smooth muscle cell. Those actin-myosin bridges which are active towards the end of a 
contraction form and break less quickly and are thought to be involved more with force 
generation whereas earlier-forming bridges contribute more to shortening. The mechanism 
for this is far from clear, but it has been postulated either that there is progressive slowing 
of normal bridge cycling, or that permanent "latch bridges" impede the cycling rate of the 
other bridges. 
Thus, studies on the neurophysiology of asthma are easier to perform on earlier 
(shortening) changes than the later (isometric) events, and it is unclear whether all the 
conclusions about smooth muscle behaviour in an in-vitro preparation are necessarily 
applicable to the state of affairs pertaining in the asthmatic's aitways, where the extent of 
contraction may be closer to the isometric end of the spectrum3. Two other properties of 
smooth muscle deserve mention The first is that of "supercontraction" - the fact that 
smooth muscle cells can contract to 10% of their optimum length explains in part the 
ts 
observation that airways subjected to bronchoconstrictive stimuli can close almost 
completely. The second is the phenomenon of reduced activation at short muscle length: 
although fibres do have the potential to shorten by 90%, the ability to contract seems to be 
less the shorter the fibrel. The mechanism for this is not clear, although it has been 
suggested that the distortion of the T-tubules that occurs as the cells become thicker may 
lead to reduced excitation-contraction coupling. 
Finally with relevance to asthma, it is found that "sensitized" muscle contracts more easily. 
The increase in myofibrillar ATPase may be due to altered ratios of myosin isoenzymes or 
to a change in light chain phosphorylation. There is also a reduction in the internal 
resistance to shortening which may be due to changes in some or all of the cytoskeletal 
proteins ( desmin, vimentin, fi)amin, non-erythrocytic spectrin, titin and nebulin)3. 
Choline®,c innervation of the bronchi. 
The nerve supply to the lung is both afferent and efferent_ 18,47,63,71 _ The efferent side is both 
excitatory and inhibitory, and involves output to airways smooth muscle, blood vessels and 
secretory tissue (mucus production). The afferent side includes the bronchopulmonary 
stretch recepts in smooth muscle, and irritant and pulmonary J receptors on epithelium and 
in the alveolar walls. Muscle cells also are connected to each other via gap junctions, and 
axon reflexes may also play a role. (For example, antidromic conduction from sensory 
stretch receptor collaterals may lead directly to smooth muscle., although local 
neuropeptide release may subserve the same ftmction. ). In some afferent fibres, "co-
transmission" of substance P, neurokinin A and calcitonin gene related peptide may 
occur'. Likewise, VIP is probably co-transmitted with acetylcholine. The simultaneous 
release of this potent vasodilator may help to increase the blood flow to contracting 
muscle, but in vitro VIP is a bronchodilator, and thus may exert a braking effect on the 
bronchoconstriction mediated by acetylcholine. 
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There are at least three4 musc.arinic receptor subtypes in the lung: M1(excitatoiy) found in 
animal parasympathetic ganglia and blocked by pirenrepine which may also inhibit reflex 
bronchoconstriction in the human lung) and~ which are probably prejunctional 
inhibitors of acetylcholine release. M3 receptors are found on smooth muscle, and their 
stimulation leads to contraction. The nomenclature of these receptors is still not completely 
unifurm. Prejunctional musc.arinic receptors on cholinergic nerves lead to reduced 
acetylcholine release when stimulated, and inflammatory mediators are thought to have an 
efrect on these receptors as well as inhibiting sympathetic inhibition and modifying 




Ml - facilitate 
M2 - inhibit 








From the above diagram it can thus be seen that a non-selective pre- and post-junctional 
blocker such as atropine or ipratropiurn could theoretically cause paradoxical 
bronchoconstriction by excessive blockade of the ~ inhibitoiy receptors. A similar sort of 
effect • has been demonstrated in guinea pigs infected with intluema virus where the viral 
neuraminidase acts selectively on the sialic acid residues of the ~ receptors, leading to 
increased bronchoconstriction. 
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Although the bronchodilator response to atropine of the normal airways implies the 
presence of basic resting vagal tone", there is little direct evidence to support the idea of 
increased cholinergic tone in asthma3• The mechanisms of the increased cholinergic effects 
in asthma are thought to include the following3: 
1. Increased afferent discharge because of epithelial damage and the 
direct effects of inflammatory mediators. 
2. Facilitation of neurotransmission by TXA (which probably also 
causes inhibition of sympathetic inhibition.) 
3. Inactivation of VIP by inflammatory cell enzymes. (Thus loss of the 
braking effect of VIP on cholinergic bronchoconstriction.) 
4. An increase in the end-organ responsiveness to acetylcholine which 
may be mediated by an increase in receptor numbers, an increase in receptor affinity, a 
post-receptor mechanism, or some combination of these. 
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2. IPRATROPIUM. 
Ipratropium is structurally very similar to atropine except that it is a quaternary ammonium 
compound (rather than tertiary)23,5.1_ It is thus positively charged and poorly lipid soluble. 
This accounts for the major phannacokinetic difference between the two compounds -
whilst inhaled atropine is rapidly distributed throughout the whole body, including the 
bra.in, ipratropium, even after intravenous administration, only crosses very poorly into the 
central nervous system. After inhalation very little systemic absorption occurs11.t7, and in 
fact a large proportion is recovered in the faeces after having been swallowed. There also 
appears to be significant first pass metabolism, with 54% of the total urinary activity of 
radio-labelled drug being due to metabolites four hours after intravenous administration, as 
opposed to 76% after oral administration53.When administered as an inhaler, the optimum 
dose is reported to be about 20 to 40 micrograms, but a higher dose of up to 500 
micrograms is recommended when using a nebuli.zer43,5.1. 











The time to maximum bronchodilating effect is } I/2-2 homs longer than that for B2 
stimulants, with a duration of effect of up to six homs53 and this may obscure relative 
efficacy in clinical comparative trials of the two preparations. Reports of side-effects are 
accumulating slowly in the literature, and probably because of the minimal systemic 
absorption, are generally described as minor. The paradoxical bronchoconstriction induced 
by earlier hypertonic formulations appears to be rare with the present funnulation 
Isolated side-effects reported with the use of ipratropium are remarkably few, but include 
the following: 
1. Transient angle closure with narrow angle glaucoma when used at the same 
time as salbutamol31. This increase can be prevented by wearing swimming goggles 
during nebulisation. 
2. Bladder outflow obstruction in the presence of prostatic hypertrophy. 41 _ 
3. Irritant contact facial dermatitist6, when used for prolonged periods in 
combination with terbutaline. 
4. Paralytic ileus in a man with spastic diplegia44. 
5. Paradoxical bronchoconstriction9• It is unclear exactly which preparation this 
patient was using, but this eftect, while theoretically explicable in terms of the 
anticholinergic effect itself, as discussed previously, is thought to be extremely rare with 
the newer formulation. 59. 
6. Transient dry mouth. 53. 
It must be emphasized, however, that the effects described above are mostly isolated case 
reports, and the drug is generally considered safe in glaucoma and the elderly23. It is also 
thought to have no significant effect on mucocilia.ry clearance23. 
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3. AN OVERVIEW OF RELATED TRIALS. 
In general, whilst there have been a large number of trials looking at the effects of 
ipratropium in both patients with asthma and those with COPDU,21,31,ss,s7, there is a much 
smaller group which have direct relevance to the issue of using nebulised ipratropium in 
the acute care situation. A brief overview of some of these is presented in Chart I. and as 
can be seen, most of them reported a favourable result. The last trial in the table 18 was the 
only one of those included not to demonstrate definite improvement, and in this case there 
was only a small number of patients with a relatively short follow-up period. Another 
trial54 (not included in the table because ipratropium was given as an inhaler with a spacer 
rather than by nebulisation) failed to demonstrate the maintenance of significant benefit 
beyond 24 hours, and the authors suggested that it could safely be discontinued beyond 
this period because of cost. 
On reviewing the trials quoted in Chart 1 several methodological difficulties become 
apparent: 
1. most of the trials contained relatively small numbers of patients ( which does 
not necessarily invalidate their conclusions). 
2.. Various dosage regimens of ipratropium were used. Although all except one36 
used a dose of 500 micrograms, the volume of solution in which this was nebulised was 
not always clearly stated, and when it was, varied from 2 to 4 millilitres. As has been 
discussed previously, this might have a significant effect on the amount of ipratropium 
being delivered to the airways. Not all the trials used multiple nebulisations - in three 
studiesSl,60,64onJy one dose of ipratropium was given. This complicates extrapolation of the 
data to the clinical setting, since most people requiring admission with acute 
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J.. Few trials have reported on a longer than 24-hour follow-up, and thus while 
demonstrated improvements in peak flow are incontrovertible, it is far from clear that these 
changes translate into earlier discharge, or even necessarily quicker resolution of the initial 
"critical" clinical state - ie stabilisation. 
23 
4 AIM OF PRESENT STUDY. 
The aim of this study was to determine whether nebulised ipratropium bromide, used as an 
adjunct to standard bronchodilator therapy in an acute asthma service, was cost-effective. 
END-POINTS 
1. Primary: Time in hours to maximum peak flow. 
2. Secondary: Admission duration measured in units of six hours (as all 
routine discharges occurred on either the morning or afternoon ward round.) 
The need for admission to either a conventional medical 
ward or the respiratory ICU was documented. 
• 
5.METHODS 
A double-blind placebo controlled trial design was adopted. 
} .Patient selection. All patients requiring admission to the Groote Schuur Hospital 
Emergency Unit's asthma room were entered in the trial after obtaining verbal informed 
consent. The study was continued until four hundred patients had been recruited. 
Although there were no formal guide-lines, medical officers acbnitting patients to the 
asthma room were expected to exclude those with end-stage chronic obstructive airways 
¥ease as judged by a history of minimal reversability and documented failure of peak 
expiratory flow rate to improve by at least fifty percent during previous admissions. 
However no formal selection criteria were imposed, as the aim of the trial was to assess the 
efficacy of the trial preparation in a functioning emergency room situation. 
2.lbndombation, Identical trial medication bottles (labelled 1 to 400) were randomised 
by the suppliers of the nebuliser solution. Two millilitres of the trial solution (containing 
either 500 micrograms of ipratropium or placebo of normal saline) was nebulised with 3 
millilitres of saline using a Hudson face-mask nebuliser driven by 100% oxygen at a flow 
rate of 6 litres/minute. 
3 .Routine medication, The standard asthma room protocol (Appendix II) which had 
been in place for the preceding six years was followed: 
i) Patients were given fum-hourly oxygen-nebuliz.ed fenoterol (1ml solution in 4ml 
saline) and the trial medication was alternated with this, also four-hourly, so that patients 
received a nebuliser every two hours . 
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ii)An aminophylline infusion ran constantly according to dosage tables (Appendix II) 
available in the asthma room designed to achieve a constant therapeutic level of 
aminophylline in the majority of cases. 
iii)Corticosteroids (methylprednisolone 125mg 12 hourly IVI) were given in the 
majority of patients, being omitted only at the discretion of the admitting clinician. 
iv)Also, where judged necessary by the asthma room medical officer, a salbutamol 
infusion was started. The ususal criterion was that the patient was seen not to be 
responding to the above therapy (For dose, see Appendix II). 
4. Di,charp criteria. An emergency room medical officer allocated for the day to the 
asthma room was responsible for all discharges. The person drawing up the duty roster 
. . 
had no connection with the trial. A patient was eligible for discharge if they satisfied all of 
the following: 1. No features of distress and able to walk to the toilet. 
2. Patient tticls able to cope at home 
3. Peak expi.ratmy flow rate shows an upward trend or has plateaued at 
>70% of best value in the past year (or >70% of predicted normal) AND morning dipping 
is not below 50% of best value in past year ( or predicted normal) 
5.Monitoring. This consisted of four-hourly peak flow measurements using a Wright's 
Mini Peak Flow Meter (done before and after fenoterol nebulization) and daily serum 
theophylline estimations. Other investigation were only done where clinically indicated 
according to the judgement of the asthma room medical officer. 
• 
26 
6 Data collection, After discharge the hospital folder was examined by the 
investigators to obtain the following data which had been collected by the admitting 
medical officer and the nursing staff in the asthma room. The form (Appendix 1) was then 
completed for each patient entered in the trial. The following information was thus 
available: 
1. Trial medication randomisation number. 
1. Height in metres . 
.1. Weight in kilograms. 
4. Year of birth. 
5. Date of admission. 
6. Time of admission. 
7. Admission peak flow rate. (In litres/minute) 
B. A second peak flow, (usually recorded after the first fenoterol nebulisation, 
at the end of the admitting officer's assessment, and prior to transfer to the asthma room.) 
9. The peak flow 24 hours after admission. 
admission. 
achnission. 
10 The peak flow 48 hours after admission. 
· 11 Whether or not the patient wason maintenance steroids prior to 
. . ' 
12. The maximum peak flow achieved. 
13. The time (in hours) .to maximum peak flow. 
14. Whether the patient was given intravenous corticosteroids 
15 Whether intravenous salbutamol was given. 
16. The serum theophylline levels on the 1st, 2nd, and 3rd day after 
17. The discharge date. 
18. The discharge time. 
19. Whether the patient requin,d ward or ICU admission . 
, 
6. STATISTICAL METHODS. 





2. One-way ANOVA tests of the quantitative covariates to assess whether 
the treatment groups differed on any of these potentially confounding factors. 
3. One-way ANOVA tests of the time to maximum peak flow and the 
number of six-hour admission units. 
4. Life-table analysis of the distributions of the times to discharge. 
7.RESULTS 
Of the original 400 patients entered, 121 were omitted from the analysis for the reasons 
shown below. The exclusions appear evenly distributed between the trial and placebo 
groups, and were made before the trial code was broken. 
Reason for exclusion IpratropiumPlacebo 
No admission PEFR 1 3 4 
Could not do PEFR 3 0 3 
Left ventricular failure 1 1 2 
Incomplete records 17 20 37 
Medication not used 3 1 4 
Nebuliser stopped early 0 2 2 
Re-admissions 35 31 66 
Clinical COPD 0 3 3 
Total ® il ill 




The analysis was done in four stages, and figures on comparability are presented for each 
of the subgroups. The composition of the groups was as follows: 
1. Phase 1 Group, This was the largest group (279 pts) and was unselected, 
representing the results of the data of allall analysable patients eptered in the trial. It 
probably most closely retlects the group of interest, being all those patients requiring 
admission who presented with features of acute bronchospasm. It was made up as follows. 
II 
Standard therapy+ ipratropium or placebo 249 
No methylprednisolone + ipratropium /placebo 11 
Salbutamol infusion + standard Rx* + ipratropium/placebo 18 
No N aminophylline + ipratropium/placebo 1 
(*Rx=therapy) 
2. Phase 2 Group. This sub-group excluded those who did not receive 
methylprednisolone and those who did receive a salbutamol infusion. It is thus the group 
which most closely follows the trial protocol, but it possibly selects out some patients with 
very reactive airways requiring salbutamol 
Standard therapy+ ipratropium/placebo 249 II 
II 
II 
3.Phase 3 Group. This subgroup of the Phase 2 analysis group selected 
those patients who were shown to have significant reversibility, in that their PEFR 
increased by more than 50% during their hospital stay. (Of importance, this definition 
could only be applied retrospectively.) 
Subgroup with >50% increase in PEFR 213 11 
30 
4.Phase 4 Group. A subgroup of the Phase 2 analysis group which showed 
> 100% increase in PEFR during admission. (Again, note that this definition could only be 
applied retrospectively.) 
Subgroup with> 100% increase in PEFR 155 II 
Tables 1 to 4 show that the base-line characteristics of the trial and placebo groups were 
very similar at all phases of the analysis, and formal statistical testing revealed no 
significant differences. The lack of complete congruity in the numbers in each group with 
regard to different variables ( eg n= 116 for height but n= 118 for weight in the trial group in 
Phase One) reflects the retrospective nature of the data collection, with some missing data. 










Mean n SD SEM 
Age 39.82 140 15.2 1.29 
Height 161.8 116 8.83 0.82 
Weight 66 118 16.6 1.53 
1st PF 140.8 136 67.9 5.82 
2nd PF 182.3 135 82.2 7.08 
Theo 1 67.92 103 31.5 3.1 
Theo 2 66.6 30 23.2 4.23 









Mean n SD SEM Total 
38.98 139 15.2 1.26 279 
161.3 108 16.2 1.56 224 
67.6 113 16 1.5 231 
145.4 135 75.1 6.51 269 
179.8 133 87.9 7.62 268 
71.26 103 30.4 3 206 
72.56 39 31.8 5.09 69 
89.44 9 57.1 19.03 15 
Theo 1, 2, & 3 = Theophylline levels on 1st, 2nd, & 3rd days. 










Mean n SD SEM 
Age 40.23 127 15 1.33 
Height 161.3 110 8.77 0.84 
Weight 66.31 111 16.8 1.6 
1st PF 143.3 127 68.5 6.08 
2nd PF 185.6 127 83.2 7.38 
Theo 1 68.9 95 32.3 3.31 
Theo 2 67.15 26 23.3 4.57 









Mean n SD SEM Total 
39.61 122 15.1 1.36 249 
162.5 98 3.39 0.85 208 
67.47 103 16.3 1.6 204 
144.1 122 71.8 6.5 249 
179.3 122 86.5 7.83 249 
72.02 95 30.7 3.15 190 
73.54 35 33.3 5.67 61 
91.63 8 60.6 21.44 14 
Theo 1, 2, & 3 = Theophylline levels on 1st, 2nd & 3rd days. 










Mean n SD SEM 
Age 40.02 111 15.4 1.46 
Height 162 97 8.84 0.9 
Weight 66.42 97 17.5 1.78 
1st PF 129.8 111 54.3 5.16 
2nd PF 174.7 111 73.5 7 
Theo 1 69.57 83 33.1 3.64 
Theo 2 67.35 23 23.6 4.93 









Mean D SD SEM Total 
38.63 102 15.1 1.5 213 
160.9 83 18 1.97 180 
67.28 85 16.8 1.83 182 
124 102 51.8 5.13 213 
164.6 102 71.7 7.1 213 
71.07 82 31.8 3.51 165 
74.32 31 34.2 6.15 54 
91.63 8 60.6 21.44 13 
Theo I, 2, & 3 = Theophylline levels on I st, 2nd and 3rd days. 










Mean D SD SEM 
Age 39.64 78 15.9 1.8 
Height 161.1 67 8.98 1.1 
Weight 64.95 68 14.8 1.8 
1st PF 110.6 78 45 5.1 
2nd PF 163.2 78 71.8 8.13 
Theo 1 68.36 58 33.6 4.41 
Theo 2 69.72 18 25.4 5.99 









Mean D SD SEM Total 
37.22 77 14.4 1.64 155 
159.6 64 19.9 2.48 131 
66.7.7 67 16.7 2.04 135 
105.8 77 40.4 4.61 155 
157 77 68.3 7. 79 155 
69.4 65 31 3.84 123 
71.89 27 34.3 6.61 45 
91.63 8 60.6 21.44 11 
Theo 1, 2, & 3 = theophylline levels on 1st, 2nd & 3rd days 
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2.0utcome. 
The endpoints of the study were the time taken to reach maximum peak flow (measured in 
hours) and the duration of admission, measured in units of 6 hours (as decisions about 
discharge, and thus ultimately the cost of the therapy, were not made more frequently than 
this). The results are shown in Table Five. (Next page.)As can be seen from the table, 
there were only minor differences at any phase of the analysis in the time taken to reach 
maximum peak expiratory tlow, the maximum flow rate achieved, or the mean peak flow 
at either 24 or 48 hours. Formal statistical testing fuund that these differences were not 
significant. Likewise, the mean number of admission units in the two groups are shown 
not to differ significantly at the first tbreee phases of the analysis. In the fuurth phase 





























TABLE 5: Outcome measures in the four phases of the analysis. 
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IPRATROPIUM PLACEBO 
Mean SD SFM n Mean SD SFM n 
GRQUPI 
PF max 315.88 86.75 7.44 136 321.05 82.8 7.18 133 
Tmax 21.11 14.33 1.23 136 22.89 15.82 1.37 133 
PF 24 281.43 87.45 10.45 70 274.5 91.74 10.39 78 
PF48 254.21 62.39 14.31 19 300.48 94.05 20.52 21 
AD Units 5.022 3.65 0.31 136 5.38 3.13 0.27 133 
Mantel Cox for Mean Ad Units Life Table analysis: p = 0. 3479 
GRQUP2 
PF max 315.83 88.35 7.84 127 319.92 82.45 7.46 122 
Tmax 20.21 13.64 1.21 127 22.89 15.42 1.4 122 
PF24 285 90.11 11.44 62 276.4 93.5 11.02 72 
PF48 255.63 67.82 17 16 307.37 94.08 21.72 19 
AD Units 4.882 3.68 0.33 127 5.32 3.04 0.28 122 
Mantel Cox/or Mean Ad Units Life Table analysis: p = 0.2309 
GRQUPJ 
PF max 318.5 85 8.07 111 321.7 79.7 7.89 102 
Tmax 21 13.8 1.31 111 23.9 15.9 1.57 102 
PF24 286 92.l 12.2 57 276.3 86.1 II 61 
PF48 -250 62.8 17.4 13 302.5 94 23.5 16 
AD Units 5.054 3.73 0.35 111 5.382 3.04 0.3 102 
Mantel Cox/or Mean Ad Units Life Table analysis: p = 0.3213 
GROUP, 
PF max 324.5 87.6 9.9 78 324.5 79.5 9.1 77 
Tmax 20.35 12.4 1.4 78 25.2 17 1.9 77 
PF24 286.8 99.6 15.6 41 278.8 92.2 13.2 49 
PF48 233.3 62 20.7 9 293.3 89.6 23.1 15 
AD Units 5.038 3.62 0.41 78 5.584 3.17 0.36 77 
Mantel Cox/or Mean Ad Units Life Table analysis: p, = 0.2077 
PF max- maximum pea.le flow; Tmax = time to PFmax~ AD Units = admission units 
8. DISCUSSION 
These results show that in a large group of patients presenting with acute wheeu, the 
addition of ipratropium to a standard asthma regime had little impact on either the time 
taken to reach maximum peak flow or the duration of hospitalisation. In both cases the 
difference between control and trial groups was of the order of 3 hours. As this trial was 
primarily designed to display cost-effectiveness, one can look at the results as follows: 
37 
1. Cost ofpehnljz,ers: These were being given every two hours. For Group One the cost is 
as follows: 
Jpratropium P/gcebo 
Number of admission units 5.02 5.38 
Hours (AdUnits x 6) 30.12 32.28 
Number of nebs ([hours/2]+ 1) 16 17 
Number of fenoterol nebs* 8 9 
Number of ipratropium nebs 8 8 
Cost offenoterol (one neb= R0.24) Rl.92 R2.16 
Cost of ipratropium nebs ( one neb = R 1.17) R9.36 R0.00 
Total cost of nebuliser solutions Rl 1.28 R2.16. 
(*The first nebuliser given was always fenoterol) 
It would thus cost an average ofR9.12 more per patient to add ipratropium to the current 
asthma room regimen, for a saving of (5.38-5.02) x 6 hours= 2.16 hours on the admission 
duration. If a patient were to be charged by the hour according to the "private" scale of 
fees, this would in fact be cost-effective treatment for the patient. (Cost per hour= Rl2.04; 
for 2.16 hours = R26.00.[Personal communication, Groote Schuur Hospital 
Superintendent's office, 1992]) In a public service hospital, however, the true cost of bed 
• 
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occupancy is far more difficult to ascertain, and a two-hour difference in occupancy is of 
marginal significance. At present patients are discharged from the asthma room at two 
times: late morning and late afternoon. From a logistic point of view, having more than 
two times of discharge during the course of the day would make little difference to the cost 
of a hospital stay, and would considerably increase the doctor and nursing workload. 
2. Cost of other medication: The theophylline infusions were made up to run over 6 hours, 
and the methylprednisolone was given every 12 hours. Thus the cost of neither of these 
would be influenced by a change in hospital stay of two or three hours. 
3. Duration ofhospjta]itmtion: It could be argued that failure to demonstrate a significant 
difference between the durations of admission of the trial and placebo groups might be due 
to inefficiency of the discharge procedure.However the trial was designed to evaluate 
efficacy of the trial preparation in a busy emergency room setting where more frequent 
than twice daily evaluations for discharge would not be feasible. Also, the lack of a 
statistically significant difference in time to maximum peak flow would suggest that this 
was not the case in the first three groups analysed. Although the difference was 
statistically significant in the fourth group (Those with a more than 100% improvement in 
peak flow), this difference of five hours was still less than the minimum time between 
discharge rounds. 
Thus at whatever level one examines the cost-effectiveness in this study, use of 
ipratropium nebulisation between standard B2 adrenoreceptor agonist doses cannot be 
justified in financial terms in a state hospital. It is important to emphasiz.e that this trial 
was not designed to look at the short term efficacy of ipratropium, and generalisations 
beyond its use in our specific hospital situation cannot.be made It appears likely that if 
case selections were made on the basis of (a) severity of airflow obstruction on admission 
, 
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and (b)knovvn capacity to reverse obstruction (i.e. true acute severe asthma), the benefits of 
the addition of ipratropium to routine therapy might have been more stiking. It is possible 
that ipratropium might prove as effective as one or other components of the standard 
regimen if used as replacement rather than in addition. In particular, it would be 
interesting to consider substituting it for intravenous theophylline in this regimen, 




The addition of ipratropium nebulisation to standard therapy in the management of acute 
severe asthma in a routine emergency unit setting was not found to be cost-effective in this 
trial. It should be noted, however, that the known beneficial effect of ipratropium bromide 
in acute asthma was almost certainly obscured in a trial which attempted to add further 
therapy to a recogniI.ed efficacious treatment regimen. The effectiveness of ipratropium 
may have been diluted further in this clinical setting by the fact that many patients had 
only mild to moderate ( <50%) reversibility of airflow limitation. 
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APPENDIX II 
ASTHMA ROOM PROTOCOLS 
The following extract is from the Groote Schuur Hospital Asthma Room management 
guide-lines: 
"TIIBRAPY: 
a. All patients receive fenoterol by nebuliser, 1 :4 ml saline, 4-hourly: in more 
distressed patients this can be given 2-hourly. 
b. Distressed asthmatics should be given oxygen by face-mask (40o/o) when they 
are not using the nebuliser. 
c. Aminophyllin: This drug should be used with extreme caution in patients: 
1. who have been using theophylline-contaioiog 
preparations prior to presentation; 
2. with impairment of liver function; 
3. with heart failure, since toxicity frequently develops. The 
administration regimen of aminophyllin is described below. 
d. Intravenous salbutamol should be used in the following cases: 
1. where aminophyllin is contra-indicated; 
2. patients who appear not to have responded to aminophyllin infusion after 
6 hours - this might be due to the fact that therapeutic aminophyllin levels have not been 
achieved, but no scientific basis for increasing the dose without knowing the theophylline 
level exists, or the patient appears to be resistant to aminophylline. 
The administration regimen for salbutamol is described below. 
e. methylprednisolone should be used in the following cases: 
1. all patients who required prednisone ( or other corticosteroid) treatment in 
the preoodiog 3 months as part of their maintenance therapy. 
2. all patients who have been in the asthma room during the preceding four 
weeks. 
3. all patients who fail to show a satisfactory response to the treatment 
outlined above within the first ONE hour after admission. "Satisfactory response" may be 
defined as improvement with regard to general state of distress, reduction of tachycardia 
and pulsus pa.radoxus and improvement of PEFR by 50% or more. 
4. patients who, on previous admissions to the asthma room showed a slow 
response curve or required i.v. corticosteroids." 
The dose of methylprednisolone is 125mg i.v. 12-hourly. 
"Admjnj3tration regimen for aroioophylJin. 
A Loading dose regimen: Give 6mg/kg (ideal body mass) over 45 min to patients who 
have not taken any thoephyllin-contaioiog preparation during the past 24 hours. 
e.g. 350mg (14ml) for 60 kg patient or 
425mg (17ml) for 70 kg patient. 
If a history of some theophyllin ingestion at home is obtained, but this is judged to have 
been inadequate to obtain therapeutic blood levels, then half of the above loading dose may 
be given. If in doubt, go straight to the maintenance dose described below. 
B Maioteoaoce dosage· To be given as a 6-hourly infusion according to the patient's lean 
body mass and adjusted after 12 hours. Since the rate of excretion is slower in patients 
who do not smoke, are elderly, have liver or cardiac failure, different infusion rates apply 
to each category of patient. 
1 Young adult smokers ( <60yrs old) :Maintenance l. l 8mg/kg/br. 
e.g. 60kg patient, give 415mg (17ml) 6-hrly 
70kg: 500mg (20ml) 6-hrly. 
for 12 hours (i.e. 2 doses) then 0.94 mg/kg/hr 
e.g. 60kg : 325mg (13ml) 6 hrly. 
70kg : 400mg (16ml) 6 hrly. 
2. Young adult non-smokers: 0.82 mg/kg/hr for 12 hours, then 0.59 mg/kg/hr 
3. Elderly patients or patients with cor pulmonale: 0. 71 mg/kg/hr for 12 hours, then 
0.35 mgi'kg/hr 
4. Patients with congestive cardiac failure or liver disease: 0.59 mg/kg/hr for 12 
hours, then 0.18 mg/kg/hr". 
"Administration tr£imen for salhuta,mol· 
Put 10 mg salbutamol in 1 litre saline ( = 10 micrograms per 1 ml) and use a 60 dpm 
microdropper giving set. 
Loadioa dose ofsalbuta,mol: 0.285 micrograms/kg/min over 15 mins. 
e.g. 60kg patient give 1. 7 ml/min for 15 mins (15ml total) 
70kg patient give 2 ml/min for 15 mins (30ml total) 
Maioteoooce dose of salbutamol: 
5 microgram/min ie. 30 microdrops/min (0.5 ml/min)" 
